title: Understanding and targeting alkylator resistance in glioblastoma.
abstract: Alkylating chemotherapy is the mainstay in the treatment of pediatric and adult glioblastoma despite primary and acquired resistance and scientific efforts to precisely define therapies for individual patients. A focus on non-MGMT-mediated temozolomide resistance for pediatric glioblastoma suggests options for new drug combinations.
authors.affiliation: Department of Neurooncology, Neurology Clinic and National Center for Tumor Diseases, University of Heidelberg and German Cancer Consortium (DKTK), Clinical Cooperation Units Neurooncology, Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. wolfgang.wick@med.uni-heidelberg.de.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Wick
authors.affiliation: Department of Neurooncology, Neurology Clinic and National Center for Tumor Diseases, University of Heidelberg and German Cancer Consortium (DKTK), Clinical Cooperation Units Neurooncology, Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Platten
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D064007:Ataxia Telangiectasia Mutated Proteins / Q000378:metabolism*; D045647:DNA Glycosylases / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D006801:Humans
chemical_list: D018906:Antineoplastic Agents, Alkylating; D064007:Ataxia Telangiectasia Mutated Proteins; D045647:DNA Glycosylases